background and objectives: typhoid is a major health problem faced by the developing countries like pakistan. more than 20 million cases are reported annually worldwide. currently fluoroquinolones are the drugs of choice to treat typhoid fever. in vivo resistance to fluoroquinolones leading to therapeutic failure is developing rapidly and is becoming a major concern for the clinicians. the obje...

Representative Claims Database: Erratum I n the article ‘‘Comparative Treatment Failure Rates of Respiratory Fluoroquinolones or b-LactamþMacrolide Versus b-Lactam Alone in the Treatment for Community-Acquired Pneumonia in Adult Outpatients: An Analysis of a Nationally Representative Claims Database’’, which appeared in Volume 94, Issue 39 of Medicine, the term ‘‘fluoroquinolones’’ was original...

The PmrA multidrug transporter protein gene was inactivated in Streptococcus pneumoniae strains CP1000 (wild-type) and EBR (mutant with enhanced active multidrug efflux). While the resistance to fluoroquinolones and ethidium bromide shown by EBR was reduced to the wild-type level, neither the susceptibility to reserpine in the presence of ethidium bromide and selected fluoroquinolones, nor the ...

Fifty strains of Staphylococcus intermedius were isolated from different pathological specimens originating from dogs during a six-month period. Antimicrobial susceptibility patterns against three fluoroquinolones were obtained on 50 Staphylococcus intermedius strains. In vitro antimicrobial susceptibility testing was performed employing the disk diffusion method (Kirby-Bauer). The sensitivity ...

INTRODUCTION Respiratory tract infections have been an important cause of morbidity and mortality worldwide that is looming large especially in context of antibiotic resistance that is confronted both by a pulmonologist as well as a general practitioner. A reflection to this trend has been the rising phenomenon of MICs as shown the respiratory pathogens towards conventional antibiotics includin...

To determine patterns and predictors of antimicrobial drug use for outpatients with community-acquired pneumonia, we examined office visit and pharmacy claims data of 4 large third-party payer organizations from 2000 to 2002. After patients with coexisting conditions were excluded, 4,538 patients were studied. Despite lack of coexisting conditions, fluoroquinolone use was commonly observed and ...